: The 28% dividend increase was a deliberate signal of management's "confidence in the future" despite the profit headwinds. This payout represented roughly 35% of earnings.
: The report from Magazin Gesundheits- und Sportnachrichten highlighted these figures during a period of global economic uncertainty and a "challenging consumer backdrop". : The 28% dividend increase was a deliberate
: Lower EBITDA margins were attributed to planned investments in new stores , marketing, and technology, as well as rising cost inflation which the company aimed to offset with price increases in 2023. : Lower EBITDA margins were attributed to planned
In 2022, Dr. Martens reported a mixed financial performance, characterized by alongside profitability pressures that led to a significant dividend increase . While the company achieved an 18% growth in underlying revenue during the first half of its financial year, it simultaneously faced "profit shortfalls" in the form of lower margins due to ongoing investments and a weakening economic environment. Key Financial Highlights (FY23 H1) While the company achieved an 18% growth in